tiprankstipranks
Trending News
More News >
Idexx Laboratories (CH:IX1)
:IX1
Advertisement

Idexx Laboratories

Compare
0 Followers

IX1 Stock Chart & Stats

Currently, no data available
Please return soon. This page is being updated.

Bulls Say, Bears Say

Bulls Say
International GrowthInternational CAG Dx recurring organic revenue growth of +13.6% was driven by volume gains including a benefit of net new customers.
Market OpportunitiesAn aging pet population from the 2020 puppy-boom and younger generations willing to spend more on their pets support a resilient pet health market.
Product InnovationThe InVue launch is progressing well, benefiting from robust adoption of IDXX's latest innovative console.
Bears Say
Product Adoption Challenges60% of non-owners do not anticipate to purchase inVue over the next year.
Revenue Growth ProjectionsRevenue growth is modeled at 8% on average for FY25-FY29, below the consensus of 9%.
Vet Visits DeclineUS vet visits have declined every quarter since 2022, posing a pressure point for IDEXX.

Idexx Laboratories News

IX1 FAQ

What was Idexx Laboratories’s price range in the past 12 months?
Currently, no data Available
What is Idexx Laboratories’s market cap?
Currently, no data Available
When is Idexx Laboratories’s upcoming earnings report date?
Idexx Laboratories’s upcoming earnings report date is Feb 09, 2026 which is in 97 days.
    How were Idexx Laboratories’s earnings last quarter?
    Idexx Laboratories released its earnings results on Nov 03, 2025. The company reported $2.753 earnings per share for the quarter, beating the consensus estimate of $2.54 by $0.212.
      Is Idexx Laboratories overvalued?
      According to Wall Street analysts Idexx Laboratories’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
        Does Idexx Laboratories pay dividends?
        Idexx Laboratories does not currently pay dividends.
        What is Idexx Laboratories’s EPS estimate?
        Idexx Laboratories’s EPS estimate is 2.36.
          How many shares outstanding does Idexx Laboratories have?
          Currently, no data Available
          What happened to Idexx Laboratories’s price movement after its last earnings report?
          Idexx Laboratories reported an EPS of $2.753 in its last earnings report, beating expectations of $2.54. Following the earnings report the stock price went same N/A.
            Which hedge fund is a major shareholder of Idexx Laboratories?
            Currently, no hedge funds are holding shares in CH:IX1

            Company Description

            Idexx Laboratories

            IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

            Idexx Laboratories (IX1) Earnings & Revenues

            IX1 Company Deck

            IX1 Earnings Call

            Q3 2025
            0:00 / 0:00
            Earnings Call Sentiment|Positive
            IDEXX Laboratories reported strong financial performance and increased its full year guidance, driven by gains in CAG Diagnostics and international markets. However, challenges such as a decline in U.S. clinical visits and wellness visits persisted, along with impacts from foreign exchange and rapid assay revenue shifts.View all CH:IX1 earnings summaries

            IX1 Revenue Breakdown

            91.70%91.70%4.75%3.13%0.42%
            91.70% CAG
            4.75% Water
            3.13% LPD
            0.42% Other
            tipranks
            Similar Stocks
            Company
            Price & Change
            Follow
            Agilent
            Illumina
            Revvity
            Zoetis
            Elanco Animal Health

            Options Prices

            Currently, No data available
            ---
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis